Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Acquires $1,000,073.36 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Todd Davis bought 35,948 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $27.82 per share, for a total transaction of $1,000,073.36. Following the completion of the transaction, the director directly owned 75,834 shares in the company, valued at approximately $2,109,701.88. This trade represents a 90.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Pelthos Therapeutics Price Performance

NYSEAMERICAN PTHS traded down $1.00 during trading hours on Monday, reaching $26.50. The company’s stock had a trading volume of 64,697 shares, compared to its average volume of 13,799. The stock has a market capitalization of $92.22 million, a price-to-earnings ratio of -1.28 and a beta of 3.17. The firm has a 50-day moving average price of $25.22. The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. Pelthos Therapeutics Inc. has a 1-year low of $11.20 and a 1-year high of $54.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million during the quarter. Equities analysts forecast that Pelthos Therapeutics Inc. will post -11.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd raised its stake in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the last quarter. Pale Fire Capital SE raised its stake in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after purchasing an additional 4,819 shares during the last quarter. Millennium Management LLC acquired a new position in Pelthos Therapeutics in the 4th quarter valued at $343,000. Geode Capital Management LLC increased its stake in shares of Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares during the last quarter. Finally, Knott David M Jr increased its stake in shares of Pelthos Therapeutics by 9.3% in the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after acquiring an additional 1,792 shares during the last quarter. 77.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PTHS shares. Piper Sandler started coverage on shares of Pelthos Therapeutics in a research note on Friday, February 27th. They issued an “overweight” rating and a $48.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price objective for the company. Finally, Oppenheimer increased their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).